Table 2

Clinical characteristics, laboratory results, treatment and recurrence of ocular syphilis in patients with HIV

										BCVA
Patient	Age	CD4, μL	HIV-RNA, copies/mL	ART	Serum RPR	NS	Main complaint	Duration of ocular symptoms before diagnosis (days)	Anatomical location	Dx	End	Treatment regimen and duration (days)	Recurrence
1	41	828	140 000	−	1:128	+	Rt: blurred vision/myodesopsia	28	Intermediate/ON	0.4	1.2	PCN 14→AP 14	−
1	41	828	140 000	−	1:128	+	Lt: blurred vision	28	Intermediate/ON	0.9	1.2	PCN 14→AP 14	−
2	31	408	37 000	−	1:256	+	Lt: LOV	12	Pan	HM	1.2	PCN 28→AP 11→DOXY 35	+
3	47	703	300	−	1:64	−	Lt: hyperaemia/FB sensation	28	Scleritis	−	−	AP 14→PCN 14	−
4	38	182	1000	−	1:64	+	Lt: LOV	730	Posterior/ON	0.3	1.0	PCN 10→CTRX 4	−
5	41	888	<20	+	1:32	+	Rt: defect of visual fields/photophobia	28	Posterior	1.2	1.2	PCN 14	−
5	41	888	<20	+	1:32	+	Lt: defect of visual fields/photophobia	28	Posterior (ASPPC)	0.6	1.2	PCN 14	−
6	32	80	140 000	−	1:128	NA	Lt: hyperaemia/FB sensation/photophobia	21	Anterior/scleritis	1.2	1.2	AP 14→AMPC 112	−
7	33	179	8400	−	1:128	+	Rt: LOV	90	Posterior/ON	0.2	0.1	PCN 14	+
8	45	379	9000	−	1:64	−	Rt: defect of visual fields	730	Pan/ON	0.9	0.8	ABPC 22	−
9	60	251	<20	+	1:512	NA	Lt: hyperaemia	210	Scleritis	1.0	−	AP 14	−
10	32	135	11 000	−	1:256	+	Rt: LOV/myodesopsia	NA	Pan	0.4	0.9	PCN 21+PSL 140	−
10	32	135	11 000	−	1:256	+	Lt: LOV/myodesopsia	NA	Pan	HM	0.6	PCN 21+PSL 140	−
11	46	604	60 000	−	1:256	NA	Rt: LOV	4	Anterior	1.2	−	PCN 14	−
11	46	604	60 000	−	1:256	NA	Lt: LOV	4	Anterior	1.2	−	PCN 14	−
12	45	659	<20	+	1:128	+	Rt: LOV	28	Posterior (ASPPC)	0.4	1.2	PCN 14	−
13	40	90	610 000	−	1:512	+	Rt: hyperaemia/pain	150	Scleritis	1.2	1.2	AP 14→CTRX 13→DOXY 15	−
							Lt: LOV/blurred vision/hyperaemia		Scleritis/posterior	0.7	1.2	AP 14→CTRX 13→DOXY 15	−
14	56	678	70	+	1:256	−	Rt: LOV	270	Posterior/ON	0.3	1.2	AP 42→PCN 10+PSL 7	−
14	56	678	70	+	1:256	−	Lt: LOV	270	Posterior/ON	0.2	0.8	AP 42→PCN 10+PSL 7	−
15	30	27	270 000	−	1:512	−	Rt: blurred vision/myodesopsia	60	Pan/ON	1.2	1.2	PCN 7→AP 14	−
15	30	27	270 000	−	1:512	−	Lt: blurred vision/myodesopsia	60	Pan/ON	1.2	1.0	PCN 7→AP 14	−
16	31	13	290 000	−	1:256	−	Rt: blurred vision/myodesopsia	42	Posterior/ON	0.2	0.6	ABPC/SBT 14	+
17	58	644	<20	+	1:4	−	Rt: LOV	150	Posterior/ON	0.1	0.2	PCN 14→AP 14	−
17	58	644	<20	+	1:4	−	Lt: −	150	Posterior/ON	0.05	0.1	PCN 14→AP 14	−
18	42	581	<20	+	1:64	−	Rt: blurred vision/myodesopsia	21	Posterior/ON	1.2	1.2	AP 4→PCN 14	−
18	42	581	<20	+	1:64	−	Lt: blurred vision/myodesopsia	21	Posterior/ON	1.2	1.2	AP 4→PCN 14	−
19	51	528	590	+	1:512	−	Lt: hyperaemia/pain	150	Scleritis	1.2	−	PCN 14	−
20	34	338	400 000	−	1:512	+	Rt: −	365	Posterior/ON	1.0	1.2	PCN 14→AP 14	−
20	34	338	400 000	−	1:512	+	Lt: LOV	365	Posterior/ON	HM	0.9	PCN 14→AP 14	−

ABPC/SBT, intravenous ampicillin/sulbactam; AMPC, amoxicillin; AP, amoxicillin plus probenecid; ART, antiretroviral therapy; BCVA, best-corrected visual acuity; ASPPC, acute syphilitic posterior placoid chorioretinitis; CTRX, intravenous ceftriaxone; DOXY, doxycycline; End, at end of follow-up; FB, foreign body; HM, hand motion; LOV, loss of vision; Lt, left eye; NA, not available; NS, neurosyphilis; ON, optic neuritis; PCN, intravenous benzylpenicillin; PSL, prednisolone; RPR, rapid plasma reagin; Rt, right eye.